ClinicalTrials.gg
RecruitingNCT07639177Updated Sep 21, 2026

Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis

A Phase 2 interventional study of lyophilised oral capsules with faecal microbiota and Placebo capsules in Rheumatoid Arthritis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital — 1 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Peking Union Medical College Hospital.

Started
2026
the only one that year
Phase 2
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital, this one is the only one that started in 2026, is one of 2 in phase 2, and was the 10th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

In this 24-week, single center, randomized, double-blind, placebo-controlled study, the efficacy and safety of lyophilised oral fecal microbiota transplantation in patients with active refractory rheumatoid arthritis will be evaluated.

Read the detailed description

Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by synovium inflammation and bone and joint erosions, leading to pain, morbidity and increased motality. Nearly half of RA patients displayed incomplete response or intolerance to the anchor drug-methotrexate. Gut microbiota plays an important role in the pathophysiology of RA and abnormal gut microeology has been documented in RA. FMT(fecal microbiota transplantation) is the engraftment of gut microbiota from healthy donors into a recipient, to ideally restore the normal gut microbial community structure. Hopefully, FMT could act as a promising strategy to improve disease control in refractory RA. Oral lyophilised fecal microbiota capsule provides a readily accessible and non-invasive way for FMT. This study will evaluate the efficacy and safety of lyophilised oral FMT in patients with active RA refractory to conventional synthetic disease modifying antirheumatic drugs (csDMARDs)with or without biological DMARDs (bDMARDs)or targeting-synthetic DMARDs (tsDMARDs).

Objectives:

To evaluate the efficacy of lyophilised oral FMT capsule in the treatment of active RA patients refractory to csDMARDs with or without bDMARDs or tsDMARDs; To evaluate the safety of lyophilised oral FMT capsule in the treatment of active RA patients refractory to csDMARDs with or without bDMARDs or tsDMARDs;

DESIGN

This is a Phase 2, randomized, 24-week, double-blind, placebo-controlled study, and 40 patients with active RA refractory to csDMARDs will be randomized in a 1:3 ratio to one of the following 2 parallel treatment arms:

Placebo group: taking placebo capsules with no microbiota inside and continue previous csDMARDs regimen simutaneously; FMT group: taking lyophilised oral capsules with faecal microbiota prepared from health donors and continue previous csDMARDs regimen simutaneously;

Placebo capsules were indistinguishable from FMT capsules by appearance and were stored in identical coded package.

Disease activity and safety profile were evaluated at 8 weeks, 16 weeks and 24 weeks.

Escape:

On week 16, all participants with no response, defined as a \<20% improvement in TJC (tender joint count), SJC (swollen joint count) and CRP (C-reactive protein) from baseline can withdraw and switch to other treatment like biologics.

Endpoints :

Primary endpoint:

ACR 20/50 response rates at 16 weeks.

Secondary endpoint:

  1. ACR70 response at 16 weeks;
  2. ACR20/50/70 response at 24 weeks;
  3. DAS 28 (CRP) and DAS 28 (ESR) at 16 and 24 weeks;
  4. EULAR response rates at 16 and 24 weeks;
  5. Health assessment questionnaire (HAQ) at 16 and 24 weeks;
  6. Patient assessment of joint pain (visual analogue scale,VAS) at 16 and 24 weeks;
  7. Patient and physician global assessment (PtGA and PhGA)at 16 and 24 weeks;
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Faecal Microbiota Transplantation
  • Refractory Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years with ;
  2. Fulfill the 2010 ACR/EULAR classification criteria for rheumatoid arthritis;
  3. Positive RF or anti-CCP antibody on screening;
  4. Active disease status with swollen joint count(SJC)≥3 and tender joint count(TJC)≥3 and ESR >25 mm/hr or hypersensitive C-reactive protein > 10 mg/L;
  5. Having received csDMARDs including but not limited to methotrexate (at a stable dose of 7.5 - 20 mg/week) for 3 months or longer prior to screening and willing to continue current regimen for the duration of the study;
  6. Other csDMARDs (e.g. Leflunomide, Iguratimod, Sulfasalazine, Hydroxychloroquine, Tripterygium Wilfordii, etc.) taking before screening with dosage stablized for 3 months or longer are permitted and should continue during the duration of the study;
  7. Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA;
  8. If taking non-steroidal anti-inflammatory drugs (NSAIDs), must be at a stable dose for at least two weeks prior to screening;
  9. Female subjects must have a negative pregnancy test unless they are surgically sterile or have been for at least one year (12 consecutive months without menses) ;
  10. Participants with fertility must use a medically effective form of and agree to continue its use during the study or at least 3 monts after the last dose of study intervention.
  11. Willing to suspend the use of other treatment for the duration of the study including acupuncture, massage, etc.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, lactating or further fertility requirements
  2. History of any inflammatory rheumatological disorders other than RA;
  3. Having used biologics or small-molecular targeting agents in 6 months prior to screening;
  4. Taking oral (GC) or get GC injection (intra-articular or parenteral) in one month prior to screening;
  5. Severe, progressive, or uncontrolled visceral disease including cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease;
  6. Severe enteritis, intestinal obstruction or bleeding, or history of gastrointestinal surgery.
  7. Active infection in recent 3 months or persistent chronic infection, including , , , tuberculosis;
  8. or history of malignancy;

8. Other conditions that investigators consider inappropriate for this study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    FMT group

    Participants of this group will take lyophilised oral capsules with faecal microbiota prepared from health donors; previous csDMARDs regimen will continue simutaneously.

    Drug: lyophilised oral capsules with faecal microbiota

  • Placebo comparator
    Placebo group

    Participants in this group will take placebo capsules with no microbiota inside; previous csDMARDs regimen will continue simutaneously.

    Drug: Placebo capsules

Interventions

  • Druglyophilised oral capsules with faecal microbiota

    Faecal microbiota is extracted from fresh stool collected from strictly screened health donors with canonical procedure, and then lyophilised and prepared into oral capsule.

  • DrugPlacebo capsules

    placebo capsules with the same appearance as FMT capsules but no microbiota inside

06

What researchers measure

Primary outcomes

  1. ACR 20/50 response rates at 16 weeks

    at week 16, the difference in ratio of participants who achieve ACR 20/50 response in two groups.

    Time frame: week 16

Secondary outcomes

  1. ACR70 response at 16 weeks

    at week 16 and week 24, the difference in ratio of participants who achieve ACR 70 response in two groups.

    Time frame: week 16

  2. ACR20/50/70 response at 24 weeks

    at week 24, the difference in ratio of participants who achieve ACR 20/50/70 response in two groups.

    Time frame: week 24

  3. DAS 28 (CRP) and DAS 28 (ESR) at 16 and 24 weeks

    at week 16 and week 24, the difference of diease activity evaluated by DAS 28 (CRP) and DAS 28 (ESR) in two groups

    Time frame: week 16 and week 24

  4. EULAR response rates at 16 and 24 weeks;

    at week 16 and week 24, the difference of EULAR response evaluated based on DAS 28 (CRP) or DAS 28 (ESR) in two groups

    Time frame: week 16 and week 24

  5. Health assessment questionnaire (HAQ) at 16 and 24 weeks;

    at week 16 and week 24, Health assessment questionnaire were evaluated and the change from baseline will be compared between two groups

    Time frame: week 16 and week 24

  6. Patient assessment of pain (visual analogue scale,VAS)at 16 and 24 weeks;

    at week 16 and week 24, pain levels (VAS) of participants were compared between two groups

    Time frame: week 16 and week 24

  7. Patient and physician global assessment (PtGA and PhGA) at 16 and 24 weeks;

    at week 16 and week 24, global assessment from participants and from care providers will compared between two groups

    Time frame: week 16 and week 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2031, 59 months after the start.

Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 59 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jun 30, 2031
CompletionEst.
Dec 31, 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07639177
Collaborators
Qingdao Haier Biotech Co., LTD
Responsible party
Lidan Zhao (Prof., Peking Union Medical College Hospital) — Principal investigator
First posted
Jun 10, 2026
Start date
Jul 1, 2026
Primary completion
Jun 30, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

Lidan Zhao
Contact
zhaolidan@hotmail.com
13810700035
Lidan Zhao
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion